Cesca Therapeutics Inc (NASDAQ:KOOL) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokers have set a 1 year consensus price objective of $10.00 for the company, according to Zacks. Zacks has also given Cesca Therapeutics an industry rank of 87 out of 256 based on the ratings given to related companies.
Several research analysts recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $6.50 price target (up previously from $1.00) on shares of Cesca Therapeutics in a report on Wednesday. ValuEngine upgraded shares of Cesca Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 2nd.
Cesca Therapeutics (NASDAQ:KOOL) last posted its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.13. Cesca Therapeutics had a negative net margin of 355.50% and a negative return on equity of 51.45%. The firm had revenue of $4.31 million for the quarter, compared to analyst estimates of $3.40 million. As a group, research analysts anticipate that Cesca Therapeutics will post -2 earnings per share for the current year.
Cesca Therapeutics Company Profile
Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.
Further Reading: What is Elliott Wave theory?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.